PH12021552024A1 - Treatment of kidney injury - Google Patents

Treatment of kidney injury

Info

Publication number
PH12021552024A1
PH12021552024A1 PH1/2021/552024A PH12021552024A PH12021552024A1 PH 12021552024 A1 PH12021552024 A1 PH 12021552024A1 PH 12021552024 A PH12021552024 A PH 12021552024A PH 12021552024 A1 PH12021552024 A1 PH 12021552024A1
Authority
PH
Philippines
Prior art keywords
kidney injury
treatment
methods
agents
treating
Prior art date
Application number
PH1/2021/552024A
Other languages
English (en)
Inventor
Stuart Alexander Cook
Sebastian Schaefer
Anissa Anindya Widjaja
Original Assignee
Nat Univ Singapore
Singapore Health Serv Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Univ Singapore, Singapore Health Serv Pte Ltd filed Critical Nat Univ Singapore
Publication of PH12021552024A1 publication Critical patent/PH12021552024A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PH1/2021/552024A 2019-02-22 2020-02-21 Treatment of kidney injury PH12021552024A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1902419.9A GB201902419D0 (en) 2019-02-22 2019-02-22 Treatment of kidney injury
PCT/EP2020/054580 WO2020169783A1 (en) 2019-02-22 2020-02-21 Treatment of kidney injury

Publications (1)

Publication Number Publication Date
PH12021552024A1 true PH12021552024A1 (en) 2022-08-22

Family

ID=65998854

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2021/552024A PH12021552024A1 (en) 2019-02-22 2020-02-21 Treatment of kidney injury

Country Status (15)

Country Link
US (3) US11339216B2 (cg-RX-API-DMAC7.html)
EP (1) EP3927742A1 (cg-RX-API-DMAC7.html)
JP (1) JP7638215B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210144708A (cg-RX-API-DMAC7.html)
CN (1) CN113748131A (cg-RX-API-DMAC7.html)
AU (1) AU2020224346B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021016613A2 (cg-RX-API-DMAC7.html)
CA (1) CA3130027A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002212A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191988A1 (cg-RX-API-DMAC7.html)
GB (1) GB201902419D0 (cg-RX-API-DMAC7.html)
MX (1) MX2021010025A (cg-RX-API-DMAC7.html)
PH (1) PH12021552024A1 (cg-RX-API-DMAC7.html)
TW (2) TWI923323B (cg-RX-API-DMAC7.html)
WO (1) WO2020169783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury
EP4260859A4 (en) * 2020-12-11 2024-05-15 Jiangsu Hengrui Pharmaceuticals Co., Ltd. USE OF A JAK INHIBITOR IN KIDNEY DISEASE
WO2023023473A1 (en) * 2021-08-16 2023-02-23 Sierra Oncology, Inc. Methods of using momelotinib to treat chronic kidney disease
CN115068442A (zh) * 2021-09-13 2022-09-20 荣灿生物医药技术(上海)有限公司 核酸的纳米颗粒组合物、其制备方法和用途
CN113960302B (zh) * 2021-09-29 2024-04-23 中国人民解放军军事科学院军事医学研究院 一种基于高内涵技术的肾毒性检测方法及其应用
WO2023086651A1 (en) * 2021-11-11 2023-05-19 Laboratory Corporation Of America Holdings Predicting a diagnostic test result from patient laboratory testing history
US20250082608A1 (en) * 2021-12-16 2025-03-13 Singapore Health Services Pte Ltd. Treatment and prevention of glomerular disease
CN114982708A (zh) * 2022-05-11 2022-09-02 成都医学院第一附属医院 一种小鼠造影剂肾病模型及其构建方法
JP7457429B1 (ja) 2022-05-20 2024-03-28 学校法人藤田学園 腎障害の治療方法または予防方法において使用するための医薬組成物および当該医薬組成物を含む併用薬、並びに、ccbl1阻害剤
GB202218388D0 (en) 2022-12-07 2023-01-18 Vvb Bio Pte Ltd GP130 antigen-binding molecules
WO2024148240A1 (en) 2023-01-06 2024-07-11 Lassen Therapeutics 1, Inc. ANTI-IL-11Rα ANTIBODIES FOR TREATING THYROID EYE DISEASE
CN119950708B (zh) * 2023-06-05 2025-12-26 北京东方百泰生物科技股份有限公司 一种抗il-11单克隆抗体的药物制剂
GB202311050D0 (en) 2023-07-19 2023-08-30 Vvb Bio Pte Ltd GP130 antigen-binding molecules
GB202405551D0 (en) 2024-04-19 2024-06-05 Vvb Bio Pte Ltd Combination treatment
WO2025238135A2 (en) 2024-05-17 2025-11-20 UCB Biopharma SRL Antibody with binding specificity for il-11
GB202408044D0 (en) 2024-06-06 2024-07-24 Vvb Bio Pte Ltd gp130 antigen-binding molecules
CN119367506B (zh) * 2024-10-14 2026-07-14 核工业总医院 一种用于治疗肾脏纤维化的药物及其应用
CN119548507A (zh) * 2024-11-12 2025-03-04 安徽医科大学 5-甲基四氢叶酸在制备治疗肾脏纤维化的药物中的应用
WO2026159121A1 (en) 2025-01-22 2026-07-30 VVB Bio Pte. Ltd. Bispecific molecules

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
ES2093562B1 (es) 1995-05-26 1997-07-01 Univ Santiago Compostela Estabilizacion de sistemas coloidales mediante formacion de complejos ionicos lipido-polisacarido.
US6649192B2 (en) 1996-07-29 2003-11-18 Universidade De Santiago De Compostela Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
NZ574028A (en) * 2006-07-05 2010-10-29 Fibrotech Therapeutics Pty Ltd Tranilast analogues (substituted cinnamoyl anthranilate compounds) for treatment of conditions associated with firbrosis
US8182814B2 (en) 2007-10-26 2012-05-22 Csl Limited Methods of treating inflammatory airway conditions by inhibition of IL-11 activity
CA2703544C (en) 2007-10-26 2016-01-05 Manuel Baca Cytokine muteins
US8518888B2 (en) 2008-10-14 2013-08-27 Csl Limited Method of treatment of gastrointestinal-type cancer with antagonistic antibodies to IL-11R
PT2953971T (pt) 2013-02-07 2023-05-02 Csl Ltd Proteínas de ligação à il-11r e suas utilizações
GB201522186D0 (en) * 2015-12-16 2016-01-27 Singapore Health Services Pte Ltd And Nat University Of Singapore The Treatment of fibrosis
CN108210909A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗脂质肾损伤的药物及其用途
CN108210893A (zh) * 2016-12-15 2018-06-29 深圳瑞健生命科学研究院有限公司 预防和治疗肾纤维化的药物及其用途
GB201621431D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore The Decoy cytokine receptor
GB201621439D0 (en) 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
US20180186871A1 (en) 2016-12-16 2018-07-05 Singapore Health Services Pte Ltd. Il-11 antibodies
US20200031920A1 (en) * 2017-04-04 2020-01-30 The George Washington University Combination Therapy for Treating Cancer
GB201716733D0 (en) 2017-10-12 2017-11-29 Nat Univ Singapore Treatment of SMC mediated disease
GB201806918D0 (en) 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
GB201809699D0 (en) 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201809700D0 (en) * 2018-06-13 2018-08-01 Singapore Health Serv Pte Ltd IL-11 antibodies
GB201902419D0 (en) 2019-02-22 2019-04-10 Singapore Health Serv Pte Ltd Treatment of kidney injury

Also Published As

Publication number Publication date
TW202037605A (zh) 2020-10-16
JP7638215B2 (ja) 2025-03-03
TW202521575A (zh) 2025-06-01
TWI923323B (zh) 2026-04-21
WO2020169783A1 (en) 2020-08-27
US12234284B2 (en) 2025-02-25
TWI874359B (zh) 2025-03-01
JP2022521591A (ja) 2022-04-11
US20250270310A1 (en) 2025-08-28
US20220403017A1 (en) 2022-12-22
GB201902419D0 (en) 2019-04-10
US11339216B2 (en) 2022-05-24
KR20210144708A (ko) 2021-11-30
EP3927742A1 (en) 2021-12-29
CA3130027A1 (en) 2020-08-27
CL2021002212A1 (es) 2022-04-18
BR112021016613A2 (pt) 2021-11-03
EA202191988A1 (ru) 2021-12-08
MX2021010025A (es) 2021-11-12
US20200270340A1 (en) 2020-08-27
AU2020224346A1 (en) 2021-10-07
AU2020224346B2 (en) 2026-05-21
CN113748131A (zh) 2021-12-03

Similar Documents

Publication Publication Date Title
MX2021010025A (es) Tratamiento de lesión renal.
PH12021552763A1 (en) Treatment and prevention of metabolic diseases
PH12021551750A1 (en) Treatment of hepatotoxicity
PH12020551923A1 (en) Methods and compositions for treating cancer
EA201891268A1 (ru) Соединения, которые можно применять в качестве ингибиторов киназы
WO2019246262A3 (en) Methods of treating or inhibiting onset of huntington's disease
MX2020008777A (es) Inmunoterapias relacionadas con el microbioma.
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2021004598A (es) Inhibidores selectivos de rgmc y el uso de los mismos.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2018014577A (es) Combinacion de anticuerpo anti-cd20, inhibidor selectivo de quinasa p13-delta, e inhibidor de btk para tratar trastornos proliferativos de celulas b.
MX2021004819A (es) Composiciones y metodos para tratar lesiones cerebrales.
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
PH12020550255A1 (en) Treatment of smc mediated disease
MX2026002367A (es) Composiciones de copolimero de bloque sensibles al ph, micelas, y metodos de uso
PH12019502578A1 (en) Methods of treatment for cervical dystonia
PH12022550078A1 (en) Enzyme inhibitors
MX2020012990A (es) Formulaciones de tegavivint y compuestos relacionados.
PH12021550121A1 (en) Methods of treating hfpef employing dapagliflozin and compositions comprising the same
ZA202103914B (en) Cxcr7 inhibitors for the treatment of cancer
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
EP4706653A3 (en) Therapeutic compositions comprising idelalisib and defactinib for treating breast cancers
MX2020012805A (es) Compuestos para el tratamiento del dolor, composiciones que comprenden los mismos, y metodos para utilizar los mismos.
WO2019190927A3 (en) Splice-switching oligonucleotides and methods of use